Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies

NCT04254107 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT04254107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04254107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Terminated
Start date
May 29, 2020
Completion date
December 1, 2023
Enrollment
133 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, cervical cancer, classical hodgkin lymphoma, cutaneous melanoma, diffuse large b-cell lymphoma, gastric carcinoma, gastroesophageal junction carcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer, ovarian cancer, peripheral t-cell lymphoma, triple negative breast cancer